Community Health Center Drug Pricing Protection Act
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, Community Health Center Drug Pricing Protection Act, changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Foreign Policy, Immigration.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section HD816C20E2D844F8E81CDCF86363AB74B: 1. Short title This Act may be cited as the Community Health Center Drug Pricing Protection Act.
- Section H458939D314FE49518B77236870C6FE56: 2. Ensuring upfront 340B discounted pricing for Federally-qualified health centers Section 340B(a) of the Public Health Service Act (42 U.S.C. 256b(a)) is...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, Community Health Center Drug Pricing Protection Act, changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Foreign Policy, Immigration
Primary Purpose
This bill, Community Health Center Drug Pricing Protection Act, changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
In CommitteeReferred to the House Committee on Energy and Commerce.
Introduced in House
Mr. Bergman (for himself, Mr. Auchincloss, Mr. Moulton, Mr. Lynch, …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → The Secretary identified in the operative section
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology